Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CAMK1D | Q8IU85 | 14/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.40 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.40 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.40 |
| ▸ | PNCK | Q6P2M8 | 1/20 | 0.40 |
| ▸ | CAMK1G | Q96NX5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751494 | 1.00 | SYK (0.46) | SYKBTKCAMK1DJAK1JAK3 | |
| SCHEMBL30751525 | 1.00 | SYK (0.46) | SYKBTKCAMK1DJAK1JAK3 | |
| SCHEMBL31673024 | 0.94 | SYK (0.40) | SYKBTKCAMK1DJAK1JAK3 | |
| SCHEMBL30751490 | 0.92 | SYK (0.56) | SYKBTKCAMK1DJAK1JAK3 | |
| SCHEMBL30751485 | 0.92 | SYK (0.56) | SYKBTKCAMK1DJAK1JAK3 | |
| SCHEMBL30751570 | 0.89 | SYK (0.41) | SYKBTKCAMK1DJAK1 | |
| SCHEMBL31673014 | 0.87 | STK17A (0.46) | CAMK1DJAK1PIP5K1CCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL31673031 | 0.86 | STK17A (0.46) | CAMK1DJAK1PIP5K1CCYP2C9CYP2C19 | |
| SCHEMBL30751574 | 0.85 | CAMK1D (0.49) | SYKBTKCAMK1DJAK1JAK3 | |
| SCHEMBL30751533 | 0.84 | PTPN11 (0.54) | CAMK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC (US) | 2025-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | SYK 201/4885BTK 34/4885CAMK1D 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.